CDKN1C‐mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib

Mantle cell lymphoma (MCL) is a rare subtype of non‐Hodgkin's lymphoma, which is characterized by overexpression of cyclin D1. Although novel drugs, such as ibrutinib, show promising clinical outcomes, relapsed MCL often acquires drug resistance. Therefore, alternative approaches for refractory...

Descripción completa

Detalles Bibliográficos
Autores principales: Kagiyama, Yuki, Fujita, Shuhei, Shima, Yutaka, Yamagata, Kazutsune, Katsumoto, Takuo, Nakagawa, Makoto, Honma, Daisuke, Adachi, Nobuaki, Araki, Kazushi, Kato, Ayako, Inaki, Koichiro, Ono, Yoshimasa, Fukuhara, Suguru, Kobayashi, Yukio, Tobinai, Kensei, Kitabayashi, Issay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177787/
https://www.ncbi.nlm.nih.gov/pubmed/33792119
http://dx.doi.org/10.1111/cas.14905

Ejemplares similares

Ejemplares similares